VELTASSA
Peakpatiromer
NDAORALPOWDER
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
VELTASSA (patiromer) is potassium ion binding activity [moa]. First approved in 2015.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELTASSA (patiromer) is an oral potassium binder powder indicated for hyperkalemia management in patients with chronic kidney disease and cardiovascular conditions. It works by binding potassium ions in the gastrointestinal tract, reducing serum potassium levels. The drug represents a non-dialysis treatment option for a common electrolyte disorder in elderly and medically complex populations.
$0.154BPart D
PeakStable
7.0 years to LOEStrong peak-stage revenue of $154M with 141K annual claims indicates a mature, stable commercial operation with established market penetration—typical of a mid-sized brand team focused on market maintenance and real-world outcomes.
Mechanism of Action
Potassium Ion Binding Activity
Pharmacologic Class:
Potassium Binder
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Started Apr 2019
1,195 enrolled
Hyperkalemia
Evaluation of Patiromer in Heart Failure Patients
Started Apr 2009
120 enrolled
HyperkalemiaHeart Failure
Why This Matters for Your Career
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.